Article

Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention.

Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-9119, USA.
Journal of psychiatric practice 04/2009; 15(2):113-24. DOI: 10.1097/01.pra.0000348364.88676.83
Source: PubMed

ABSTRACT Attrition from treatment in the short and long term for major depressive disorder (MDD) is clearly an adverse outcome. To assist in tailoring the delivery of interventions to specific patients to reduce attrition, this study reports the incidence, timing, and predictors of attrition from outpatient treatment in public mental health clinics.
Outpatients with psychotic and nonpsychotic MDD receiving measurement-based care in the Texas Medication Algorithm Project (N=179) were evaluated to determine timing and rates of attrition as well as baseline sociodemographic, clinical, and attitudinal predictors of attrition.
Overall, 23% (42/179) of the patients left treatment by 6 months, and 47% (84/179) left by 12 months. Specific beliefs about the impact of medication, such as its perceived harmfulness, predicted attrition at both 6 and 12 months. Younger age (P=0.0004) and fewer side effects at baseline (P=0.0376) were associated with attrition at 6 months. Younger age (P=0.0013), better perceived physical functioning (P=0.0007), and more negative attitudes about psychiatric medications at baseline (P=0.0075) were associated with attrition at 12 months.
Efforts to elicit attitudes about medications and tailoring educational and other retention interventions for patients with negative beliefs about antidepressants both when initiating a new medication and throughout treatment may reduce attrition. Particular focus on younger patients and those requiring frequent visits may be helpful.

0 Bookmarks
 · 
87 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Modern pharmacological treatments for anxiety disorders are safer and more tolerable than they were 30 years ago. Unfortunately, treatment efficacy and duration have not improved in most cases despite a greater understanding of the pathophysiology of anxiety. Moreover, innovative treatments have not reached the market despite billions of research dollars invested in drug development. In reviewing the literature on current treatments, we argue that evidence-based practice would benefit from better research on the causes of incomplete treatment response as well as the comparative efficacy of drug combinations and sequencing. We also survey two broad approaches to the development of innovative anxiety treatments:the continued development of drugs based on specific neuroreceptors and the pharmacological manipulation of fear-related memory. We highlight directions for future research, as neither of these approaches is ready for routine clinical use.
    Journal of anxiety disorders 08/2012; 26(8):833-843. DOI:10.1016/j.janxdis.2012.07.009 · 2.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Identifying characteristics that influence smoking behavior among military personnel is critical to protect health and operational functioning. This study prospectively examined rates of cigarette smoking and predictors of changes in smoking behavior as a function of Iraq deployment. One thousand eighty-two US Army soldiers (n = 773 Iraq-deployed; n = 309 nondeployed) completed assessments at two sessions [time 1: April 2003-July 2004; time 2: May 2004-July 2004 (nondeployers); January 2005-September 2006 (deployers)]. Approximately 48 % of participants smoked at both time points, with 6 % initiating smoking and 6 % quitting. Smoking initiation was associated with warzone stress exposure; female gender and high military unit support predicted cessation. Military rank and alcohol use were associated with both smoking initiation and cessation. Findings highlight the potential benefits of targeting risk factors for cigarette smoking in comprehensive military health programs aimed at smoking prevention and cessation.
    Annals of Behavioral Medicine 01/2014; 48(1). DOI:10.1007/s12160-013-9584-5 · 4.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: To identify specific quantitative and qualitative factors that govern the decision to adhere or decline antidepressant medication in antenatal women with moderate-to-severe mood and anxiety disorders. METHODS: Fifty women (30 adherers, 20 decliners) were recruited between 18 and 34 weeks gestation in a tertiary care clinic for perinatal mothers. They were prospectively monitored 4 weeks apart up to 1-month postpartum on the: Hamilton Anxiety Scale, Hamilton Depression Scale, Mood Disorders Insight Scale, Antidepressant Compliance Questionnaire, Penn State Worry Questionnaire, and NEO Personality Inventory. Qualitative interviews were conducted at baseline. Hierarchical linear modeling determined illness trajectories of the two groups. RESULTS: Significantly different course of illness was observed in adherers versus decliners. Adherers had healthier attitudes toward depression and compliance with medication (P < .005). Decliners had less illness insight (P < .001) and cited fear of fetal exposure, and thought medication was unwarranted. CONCLUSIONS: Pregnant women experienced significantly divergent illness trajectories depending on if they accepted antidepressant medication therapy for their illness. Risk perception, attitudes, and illness insight impacted decisions surrounding adherence and decline.
    Depression and Anxiety 11/2013; 30(11). DOI:10.1002/da.22137 · 4.29 Impact Factor

Full-text (2 Sources)

Download
9 Downloads
Available from
Aug 11, 2014